Through the adenosine monophosphate-activated protein kinase (AMPK)-dependent suppression of androgen signaling pathway and insulin-like growth factor-1 (IGF-1), metformin inhibits proliferation of prostate cancer. This evidence concerns the gene IGF1 and prostate cancer.